Revive Therapeutics Stock News

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) told investors it is on track to complete study enrollment of its Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine

 Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, January 17, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare di...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued a progress update on its psilocybin pharmaceutical programs ahead of the first clinical study on psilocybin for methamphetamine use disorder

 Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, January 6th, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therape...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) told investors it expects to complete patient enrollment of its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19) in the first quarter of

Approximately 700 subjects participated in the enrollment period Expected to begin subject enrollment in Turkey by mid-February Expected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF ) (CSE: RVV ) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, wishes to clarify certain disclosures in its press release titled "Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19," issued on December 29, 2021 that provided an update on the Company''s U.S. Food & Drug Administration ("FDA") Phase 3 clinical trial (the "Study") ( NCT04504734 ) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. As of December 29, 2021, there were approximately 700 subjects that participated in the enrollment period of the Study.

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that its U.S. Food and Drug Administration (FDA) Phase 3 clinical trial study evaluating the safety and efficacy of Bucillamine— an oral drug

TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has decided to expand research with Bucillamine, an oral drug shown to have promising anti-viral and anti-inflammatory capabilities and is being evaluated in a current Phase 3 clinical study for COVID-19, as a potential treatment for the Omicron variant (B.1.1.529).

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has decided to expand research with Bucillamine as a potential treatment for the coronavirus Omicron variant.  It is an oral drug shown to have

Specialty life sciences company focused on developing drugs for rare disorders and infectious diseases Advancing clinical development of gout drug Bucillamine for infectious diseases, including COVID-

TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation ("ODD") for Bucillamine for the prevention of ischemiareperfusion injury (IRI) during liver transplantation.

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) revealed that it has filed an application with the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for Bucillamine for the

 Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled "Thiol drugs decrease SARS-CoV-2 lung injury...

TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro from the University of California, San Francisco, showing that potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2), which is now globally dominant, and also reducing SARS-CoV-2-related lung injury in vivo and providing strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. In addition to its anti-oxidant and anti-inflammatory properties that could limit lung injury in COVID-19, thiol drugs have promising antiviral effects.